Get email updates from SABCSMeetingNews.org
Subscribe to get regular news updates from SABCS.org and SABCS Meeting News.
Pedram Razavi, MD, PhD, moderated a Wednesday session that leveraged challenging, complex clinical cases to highlight how the range of expertise of a molecular tumor board (MTB) can inform and help optimize patient care and treatment in real-world practice.
AACR Distinguished Lectureship recipient Kornelia Polyak, MD, PhD, FAACR, on Thursday discussed her work on disease transition and profiling the different cell types involved in different stages of breast disease.
Presenters including Calvin J. Kuo, MD, PhD, discussed basic science developments such as the role of organoids, single-cell sequencing, clinical genomics, and molecular docking.
Saturday morning’s Career Development Forum, for preregistered attendees, will feature concurrent workshops focusing on clinical trials, grant writing, and career goals.
Findings from 10 studies, including IDEA, PREFERABLE-EFFECT, and POSITIVE, were presented Thursday during the second General Session of the 2023 SABCS®.
SABCS® Program Director Kate Lathrop, MD, shares a few highlights from Friday’s schedule to help you plan your day, including notable presentations, award lectures, and more.
Don’t miss Friday’s General Session abstract presentations and Poster Spotlight Session presentations, featuring research that has the potential to shape the future of breast cancer care.
Presenters on Tuesday discussed data and regulatory considerations for three recently approved targeted therapies—trastuzumab deruxtecan (T-Dxd), elacestrant, and capivasertib.
Two sessions on Friday afternoon will distill notable recent developments in breast cancer research and clinical practice into four hours of must-attend presentations.
Per Hall, MD, PhD, discusses a Friday afternoon presentation on the KARISMA-2 low dose tamoxifen trial.